Search

• This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing non-oncogene-addicted mNSCLC. • ESMO-MCBS scores are given to describe the levels of evidence for treatment choices. • ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies. • Recommendations are based on available scientific data and the authors' collective expert opinion. • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach. [ABSTRACT FROM AUTHOR]

• This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing oncogene-addicted mNSCLC. • ESMO-MCBS scores are given to describe the levels of evidence for treatment choices. • ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies. • Recommendations are based on available scientific data and the authors' collective expert opinion. • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach. [ABSTRACT FROM AUTHOR]